Stocks and Investing
Stocks and Investing
Tue, May 9, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
John Newman Maintained (ATRA) at Strong Buy with Increased Target to $500 on, May 9th, 2023
John Newman of Canaccord Genuity, Maintained "Atara Biotherapeutics, Inc." (ATRA) at Strong Buy with Increased Target from $1,250 to $500 on, May 9th, 2023.
John has made no other calls on ATRA in the last 4 months.
There are 3 other peers that have a rating on ATRA. Out of the 3 peers that are also analyzing ATRA, 0 agree with John's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with John
- Anthony Butler of "EF Hutton" Reiterated at Strong Buy and Held Target at $625 on, Thursday, February 9th, 2023
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $675 on, Thursday, February 9th, 2023
- Salim Syed of "Mizuho" Reiterated at Strong Buy and Held Target at $775 on, Tuesday, February 7th, 2023
Contributing Sources